BioMerieux : Résultats annuels 2020 - 24 février 2021
March 15, 2021
Share
FY 2020 Results & 2021 Outlook
Investor Presentation - February 24th, 2021
P I O N E E R I N G D I A G N O S T I C S
DISCLAIMER
This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.
2
AGENDA
OVERVIEW OF bioMérieux
FY 2020 ACTIVITY REVIEW
FY 2020 FINANCIAL RESULTS
CSR AMBITION
2021 OUTLOOK
KEY TAKEAWAYS - 2020 PERFORMANCE
SALES
€3,118m
+19.7%
at constant exchange rates and scope of consolidation
FREE CASH FLOW
€328m
4
PROFITABILITY
€613m
19.6%of sales vs. 14.5% in 2019
LEVERAGE
0.1x EBITDA
BUSINESS TRENDS
Molecular biology
Microbiology
Immunoassays
Industry
COMPREHENSIVE COVID-19
IN VITRO DIAGNOSTIC SOLUTION
EXTRACTION
PCR TEST
SYNDROMIC
SEROLOGY
ARGENE®
SARS-CoV-2R-GENE®
VIDAS®
EMAG® &
SARS-Cov-2 RESPI R-GENE®
BIOFIRE® RP2.1
anti-SARS-CoV-2 IgM
EASYMAG®
BIOFIRE® RP2.1plus
anti-SARS-CoV-2 IgG
High quality and fully
Ready-to-use kits with internal
Rapid, easy, automated syndromic
Fully automated qualitative assays
automated RNA extraction
controls allowing mid-to-high
testing of 22 or 23 pathogens
for the detection of antibodies
prior to amplification
size batch analyses on most
that cause respiratory infections,
in patients who have been exposed
and detection
real-time PCR systems. The
including SARS-CoV-2
to SARS-CoV-2
5
Single plex SARS-CoV-2R-GENE® may be used on saliva and oropharyngeal (throat) swab specimens
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
Original document
Permalink
Disclaimer
BioMérieux SA published this content on 16 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 April 2021 09:35:05 UTC.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.7%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.3%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (31.3%), North America (45.4%), Asia/Pacific (17.4%) and Latin America (5.9%).